TickerFacts.

LENZ Therapeutics, Inc. (LENZ): Cost of Revenue

Annual figures by period end, from SEC filings.

$418.0K
Year ended 2025-12-31
$1.77M
Trailing 12 months to 2026-06-30
2024-12-31: $02025-12-31: $418.0K$418.0K
2024-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$418.0Kn/a2026-03-24, From 2025-01-01
2024-12-31$0n/a2026-03-24, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
LENZ Therapeutics, Inc. (LENZ)2025-12-31$418.0Kn/a
Pelthos Therapeutics Inc. (PTHS)2025-12-31$3.99Mn/a
Lineage Cell Therapeutics, Inc. (LCTX)2024-12-31$334.0K-50.2%
Scilex Holding Co (SCLX)2025-12-31$10.60M-36.5%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$5.76M+622.3%
Alpha Cognition Inc. (ACOG)2025-12-31$603.4Kn/a
Kymera Therapeutics, Inc. (KYMR)2025-12-31$39.21M-16.7%
Protalix BioTherapeutics, Inc. (PLX)2025-12-31$26.99M+11.0%
Champions Oncology, Inc. (CSBR)2026-04-30$30.90M+8.8%

Compare LENZ, PTHS, LCTX, SCLX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗